Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04948099 | A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases | PHASE1 | COMPLETED | 73 | — | — | Jul 6, 2021 | Jul 3, 2023 | Dec 13, 2024 | 11 | United States, Poland |
| Arm | Type | Description |
|---|---|---|
| VIB1116 | EXPERIMENTAL | Single dose of VIB1116, SC or IV administration. Multiple doses of VIB1116, SC administration. |
| Placebo | PLACEBO_COMPARATOR | Single dose of Placebo, SC or IV administration. Multiple doses of Placebo, SC administration. |
| Name | Type | Description |
|---|---|---|
| VIB1116 | DRUG | VIB1116 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Male or female ≥ 18 years of age and ≤ 60 years of age and a body mass index (BMI) \< 30 kg/m² or, in patients who have completed dosing with a vaccine against COVID-19 and are at least 1 month post the last dose, ≤ 65 years of age and BMI \< 35 kg/m\^2 * A diagnosis of one of...